Uploaded June 2026 | Updated September 2026, 3 hours ago
🎬 This is a clip from The Feldman Protocol #99 with Chris Masterjohn (PhD). Watch the full episode here: `youtu.be/gKMS_rDs55c`
Chris Masterjohn makes the case that only two long-term double-blind randomized controlled trials on seed oils have ever been conducted — and both point toward harm for heart disease and cancer. He argues that short-term trials structurally miss the damage because oxidative liability accumulates over years, not weeks.
🔥 This episode is sponsored by us --
Own Your Labs 👉 `ownyourlabs.com/tfp/99`
Private blood testing services
🩸Over 300 blood tests
💰Extremely affordable
❤️ We love our customers
(Yes, we are literally funding the entire podcast from our own company -- so if you want to show your support, keep getting your private blood testing through our service. Thank you! 🙏)
🔗 CONNECT WITH DAVE FELDMAN:
Main Channel: `youtube.com/@realDaveFeldman`
X/Twitter: `https://x.com/realDaveFeldman`
Instagram: `instagram.com/realDaveFeldman`
Website: `https://thefeldmanprotocol.com`
#FeldmanProtocol #DaveFeldman #ChrisMasterjohn #SeedOils #PUFA #OxidativeStress #HeartDisease #Cancer #NutritionScience #LipidPeroxidation #RandomizedControlledTrial #AncestralDiet #MetabolicHealth #NutritionResearch #ClinicalTrials
🎬 This is a clip from The Feldman Protocol #99 with Chris Masterjohn (PhD). Watch the full episode here: `youtu.be/gKMS_rDs55c`
Chris Masterjohn makes the case that only two long-term double-blind randomized controlled trials on seed oils have ever been conducted — and both point toward harm for heart disease and cancer. He argues that short-term trials structurally miss the damage because oxidative liability accumulates over years, not weeks.
🔥 This episode is sponsored by us --
Own Your Labs 👉 `ownyourlabs.com/tfp/99`
Private blood testing services
🩸Over 300 blood tests
💰Extremely affordable
❤️ We love our customers
(Yes, we are literally funding the entire podcast from our own company -- so if you want to show your support, keep getting your private blood testing through our service. Thank you! 🙏)
🔗 CONNECT WITH DAVE FELDMAN:
Main Channel: `youtube.com/@realDaveFeldman`
X/Twitter: `https://x.com/realDaveFeldman`
Instagram: `instagram.com/realDaveFeldman`
Website: `https://thefeldmanprotocol.com`
#FeldmanProtocol #DaveFeldman #ChrisMasterjohn #SeedOils #PUFA #OxidativeStress #HeartDisease #Cancer #NutritionScience #LipidPeroxidation #RandomizedControlledTrial #AncestralDiet #MetabolicHealth #NutritionResearch #ClinicalTrials




![BREAKING – New Analysis of Heart Scan Data (CCTA) for Extremely high LDL vs Average LDL Cholesterol
BREAKING: Dr Matt Budoff has now presented the matched analysis for:
KETO (#LMHRstudy) vs Control (#MiHeart)
METHODS – 80 Participants of #LMHRstudy fell within #MiHeart age range and were then matched 1:1 for age, gender, race, diabetes mellitus, hyperlipidemia, hypertension, and past smoking to asymptomatic subjects from the #MiHeart cohort.
PRIMARY ANALYSIS – High resolution heart scans (#CCTA) allowing for primary analysis of Total Plaque Score (TPS), Total Stenosis Score (TSS) and Segment Involvement Score (SIS)
RESULTS
The matched mean age was 55.5 years, with mean #LDL cholesterol of 272 mg/dL (max LDL-C 591) mg/dl and mean 4.7 years duration on a ketogenic diet.
🚨 There was no significant difference in coronary plaque burden of #LMHRstudy (mean LDL-C 272) cohort as compared to #MiHeart controls (mean LDL 123 mg/dl); nb: pre-KETO LDL-C in KETO group was 122 mg/dl
🚨 There was no significant difference in CAC (median and IQR) [0 (0,56)] versus [1 (0, 49)], p = 0.520
🚨 No relationship of LDL-C elevations and plaque
⚠️ is still ongoing for second CCTA completion in our cohort by February of 2024. And as always, please continue to work with your doctor.
- I will have my own video reaction and thoughts in the coming hours.
🙏🙏🙏 to everyone and I mean everyone who helped us get to this pivotal milestone. 🙏🙏🙏 BREAKING – New Analysis of Heart Scan Data (CCTA) for Extremely high LDL vs Average LDL Cholesterol](https://i.ytimg.com/vi/ny2JqAgoORo/mqdefault.jpg)





![#CholesterolScience – with Ethan Weiss, MD
Hosted by Dave Feldman :: Produced by Siobhan Huggins
0:00 Intro and Ethan’s background
3:33 Cholesterol Skeptics and Concerned Medical Professionals – meeting in the middle.
( https://cholesterolcode.com/wp-content/uploads/2019/08/CholesterolScience-with-Ethan-Weiss.png )
8:20 How many patients does Ethan feel reach a decent level of knowledge about lipidology and cardiology?
10:15 Navigating the discussion on the benefits/risks of lipid changes from diet
17:15 When cholesterol is elevated for a metabolic reason alone – does it pose a greater risk?
( https://cholesterolcode.com/wp-content/uploads/2019/08/CholesterolScience-with-Ethan-Weiss-1.png )
( https://cholesterolcode.com/wp-content/uploads/2019/08/key-question.png )
23:00 Giving doctors the benefit of the doubt – are doctors just trying to help?
27:10 Dave’s disappointment with perceived lack of curiosity from the medicalsphere.
30:15 The difficulty in discussing possible benefits from lipoproteins and potential influence on all-cause mortality
36:50 Nuances of data collection and statin trials
- Study mentioned: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09327-3/fulltext
Note from producer:
In the efficacy and safety statement for the trial mentioned it lists Merck Sharp & Dohme (manufacturers of simvastatin) as well as Hoffmann-La Roche (manufacturers of the vitamins used) as providing partial funding for the study:
The study is being funded by the UK Medical Research Council, the British Heart Foundation, Merck Sharp & Dohme (manufacturers of simvastatin[…]) and Hoffmann-La Roche (manufacturers of the vitamins[…]) https://doi.org/10.1053/euhj.1998.1350
- However in the published paper of the results it states the following:
The Clinical Trial Service Unit has a staff policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings. https://doi.org/10.1016/S0140-6736(02)09327-3
44:56 If there were a trial that showed that people with high HDL, high LDL, and low triglycerides didn’t benefit from statins would [Ethan] want to know that information? (https://twitter.com/erreyedoc/status/1162070100037574656)
- Study mentioned: Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S https://www.ahajournals.org/doi/full/10.1161/hc5001.100624
52:40 Open data, machine learning, and possibilities moving forward
56:20 Non-HDL and mortality from the NHANES dataset
https://twitter.com/DaveKeto/status/1133177415486693376?s=20
58:30 Changes in ability to connect with researchers and scientists
1:00:05 What does Dave mean by risk?
1:04:10 Modifications to low carb to achieve lower LDL
1:08:55 What Dave has learned about the importance of rigorousness in self-experimentation
1:13:29 Can self-experiments have benefits applicable to people beyond the person doing them?
1:17:29 Cholesterol biosynthesis
1:18:40 Reverse causality – is there a possibility that the lipoproteins are reflecting a problem and not causing it?
Note from producer: I attempted a follow-up to see if I could find any studies looking at the impact of infusion of native mouse lipoproteins on atherosclerosis development, but I have not found any thus far.
1:24:33 Clotting, vascular injury, and engineering
1:29:55 The impact of placebo
Podcast mentioned: The Hidden Brain: The Untapped Potential of Placebos to Heal (transcript available) https://www.npr.org/2019/04/29/718227789/all-the-worlds-a-stage-including-the-doctor-s-office
1:33:23 The impact of seeing lipids change – could this impact the results of the study?
1:35:56 If it were dose dependency would all drugs that lower LDL have a likewise decrease in cardiovascular disease mortality?
1:38:46 Drug trials – ideals, replication, and funding
1:42:35 Wrap up and outro
Ethan Weiss Contact:
Twitter: @ethanjweiss #CholesterolScience – with Ethan Weiss, MD](https://i.ytimg.com/vi/phfHRZ_aME8/mqdefault.jpg)